The Johnson & Johnson vaccine just got FDA EUA approval. Here is a summary of what we know so far.
I’d like to finish our series on Optimize Your Energy addressing fatigue, low energy, and stress. In this this final segment I’d like to review with you the third myth on resolving these issues, outline a strategy, and offer a mentorship program. We’ll also do a brief update on monoclonal antibodies and COVID-19.
The 3rd myth I’d like to mention is the myth to employ strategies as needed to address the causes to resolve fatigue, low energy and stress. The reality is that a systems approach is needed, follow the correct sequence of steps to resolve fatigue, low energy and stress. You need to follow the correct sequence of steps, a systems approach, but the steps may need to be repeated on reassessment to resolve fatigue, low energy and stress. A systematic approach means a rational step by step sequence, allows for reproducible results, follows a proven successful system that reaches the desired goal, and accounts for individual needs. I’ve found that a 5 step process is the most effective: Remove the exposures or eliminate the infection / overgrowth/ imbalance, Replace / Replenish nutrients, deficiencies, energy reserves, Re-inoculate the microbiome, Repair the involved organs/ tissue to allow for detoxification, Rebalance the lifestyle, stressors, sleep, etc.
To start you want to evaluate for all possible causes. Going through the history, examinations, and labs with a fine tooth comb. Organizing the history, exam, and symptoms in order to analyze for causes. Removing the identified toxic or immune provoking exposures after a thorough analysis is the first step. Examples include heavy metals, chemical toxins, molds, infections, allergies, negative emotional patterns, electromagnetic frequencies. Replacing or replenishing nutrients deficiencies or energy reserves may done second or started even concurrently with the first step. Here are some examples of deficiencies to replace: Lifestyle habits (sleep, food, water), All nutrients (vitamins & minerals), mitochondria, immune tolerance (sensitivities), all hormones (adrenals, thyroid, sex). Optimizing the involved organs or tissues in detoxification need to be done before detoxification. This includes in the intestinal / microbiome system, hepatic /biliary system, kidney /urinary system, skin and lymphatic system, and brain lymphatic/ microglia system.
In order to resolve fatigue, low energy or stress you need to undergo a system that remedies all causes, is personalized, is rationally thought out, and has a successful track record. In our programs we have optimized energy to resolve fatigue, low energy, and stress by giving guidance through the Functional Medicine Matrix giving a map to navigate to faster resolution and having more lasting energy.
Optimizing energy means you can wake up energized in the morning ready to accomplish the days goals , achieve the next level of career success, be present and fully engaged with you family and loved ones, spend more time with children or loved ones, and avoid wasting 2 months of the year from fatigue and being nonproductive.
One pearl that I’ve found is to reach your goals in the most efficient manner is to fina mento or guide who has accomplished what you want through a system that works. This has been true of people seeking to speak better hiring an accomplished speaker, a music student trying to learn an instrument from a professional performer, and golfer learning from a PGA tour player.
A mentor can save you time by avoiding failure that they’ve experienced, guiding you to the fastest most efficient path to the goal, and use a system that has worked with many different people.
So at this point, I’ve shared with you the three broad categories of causes for fatigue, low energy, and stress. We went through the importance of complete history taking, labs, and analyzing symptoms. Just now we reviewed a 5 step process as part of a system to optimize energy. If you want to optimize energy, resolve fatigue, low energy, or stress you can use what I’ve shown you, or continue to do the things that you’re currently doing, or call (925) 736-9828 or email firstname.lastname@example.org for a consultation to get an evaluation, have a customized plan created for your goal, and mentorship and support.
People have tried to do it themselves often following the steps of starting with their primary care physician, then doing online research and book reading, then listening to summits and podcasts, and then seeing natural and functional practitioners. We can help you with a system that can save you time, provide education and provide ongoing mentorship and support. So call us to help optimize your energy, resolve fatigue, low energy, or stress.
Moving on to an update on a possible treatment for COVID-19 and also prevention I want to discuss with you Eli Lilly’s promising monoclonal antibody. We make antibodies to infectious agents such as the coronavirus. The initial use of antibodies was from taking plasma from survivors of an infection we are trying to treat to transfuse into a sick patient so antibodies from the donor can neutralize the infectious particles or infectious agent in the recipient. The problem is that the plasma may contain a mix of antibodies some more effective and helpful than others and in different concentrations. So while the survivor has the cells to make more antibodies and adjust the amounts in a reinfection, the recipient only passively receives the antibodies “as is.” What Eili Lilly did, and how monoclonal antibodies are usually made and utilizied is to take the most effective antibodies that have been created by the survivors and “clone” high concentrations of them so that a very effective treatment is created. The antibody from Eli Lilly is called Ly-COV555 and it binds very effectively to the coronavirus. The first article I want to show you is form Science which describes a trial of 452 patients with mild to moderate SARS-CoV-2 diagnosed within 3 days of enrollment and who were not hospitalized. They received the Ly-Cov555 antibody in 3 different dosages. Five of 302 patients who received the drug ended up being hospitalized—1.7%. But nine of the 150 placebo patients ended up in the hospital—6%—meaning there was a 72% reduced risk of being hospitalized for patients who received the antibody versus those who received a placebo. So if you carry out the math this means you would need to treat 23 people to prevent 1 hospitalization. The drug would have to be given subcutaneously or intravenously as an outpatient to prevent hospitalization. The drug produced no serious side effects, the company reports. Interestingly only the middle dose of the antibody reached the trial’s primary goal: a significant reduction of the load of coronavirus in the blood of patients after 11 days. Lower and higher doses did not meet this mark. More research is obviously needed and plans for larger 800 patient trial is pending.
In a related article the NIH, is looking to enroll participants in 2 phase 3 trials to test if using monoclonal antibodies can prevent infection by SARS-CoV-2 coronavirus. Many of the investigators are part of the COVID-19 Prevention Network, recently established by the National Institute of Allergy and Infectious Diseases (NIAID), one of the National Institutes of Health. According to the NIH press release “One trial is being conducted jointly by NIAID and trial sponsor Regeneron Pharmaceuticals of Tarrytown, New York. It will evaluate Regeneron’s investigational double mAb combination, REGN-COV-2, which is designed to bind to two points on the SARS-CoV-2 spike protein and prevent it from entering healthy cells. The trial will enroll approximately 2,000 asymptomatic adults who are household contacts of persons with SARS-CoV-2 infection. Participants must have been in close contact (typically due to residing at the same address) with the infected person in a 96-hour window preceding administration of either REGN-CoV-2 or placebo. In addition to assessing safety, the trial will seek to define whether REGN-COV-2 can prevent infection or disease symptoms in those already infected. The efficacy assessment will be a one-month period following administration of REGN-COV-2 or placebo. All trial participants will be followed for safety for seven months after efficacy assessment period ends.”
“A second trial, sponsored by Eli Lilly and Company of Indianapolis, Indiana, and implemented in collaboration with NIAID, will evaluate LY-CoV555, a mAb isolated from a recovered COVID-19 patient by scientists at AbCellera (Vancouver, British Columbia, Canada) and the NIAID Vaccine Research Center, and developed by Eli Lilly and Company. This trial will assess whether LY-CoV555 can prevent SARS-CoV-2 infection among people at high risk of exposure due to residing or working in skilled nursing or assisted living facilities. Within one week of identification of a case of SARS-CoV-2 infection at a facility, study investigators will enroll trial volunteers and evaluate the prevention efficacy and safety of LY-CoV555, compared to placebo, over an 8-week period. The trial will also evaluate efficacy in preventing symptoms of a given severity in those already infected. Participants will continue to be followed for safety for an additional 16 weeks. Up to 2,400 participants will be randomized to receive intravenous infusion of either LY-CoV555 or placebo.”
Therefore, monoclonal antibodies may be a potential treatment option and perhaps a preventative measure as well. Some monoclonal antibodies can last for months so that they possibly be used as a temporary “vaccination” to be protective against COVID-19, and may be an alternative if vaccines are not available although pricing may be a factor. I’ll keep you up dated as we get more information.
If you have comments, questions, or want to learn how functional medicine can help with improving your gut, maintaining brain health, and optimizing immune function call our office at (925) 736-9828 or email email@example.com.
For more information on supplements to boost your immune system click on this link, call our office at (925) 736-9828, or email firstname.lastname@example.org.
Take Care and Stay Healthy.
Jeffrey Mark, M.D.
You Might Also Enjoy...
The Johnson & Johnson vaccine just got FDA EUA approval. Here is a summary of what we know so far.
Recent guidelines have changed from the FDA regarding mercury amalgam removal. We review what safe removal should look like. If you elect for removal you also need detoxification to prepare before, during and afterwards.
One in two thousand people across the globe have a gastrointestinal immune related condition where they may have trouble swallowing called eosinophilic esophagitis. Here is what you should know and what we can do to help.
Autoimmunity is on the rise. 70% of your immune system is in your gut. Reset your gut, reset your immunity with IgX
Novavax shows promise in UK and South African Phase 3 trial numbers so are. We are closer to getting Johnson and Johnson's vaccine in the U.S. Variants are a big wildcard for the current vaccine programs.
In Small Intestinal Bacterial Overgrowth or SIBO, fermentation increases in the small intestine, so even healthy diets can cause gas, bloating and intolerance to certain foods and probiotics. Here is an illustration of how BioSpore can help.